PL351794A1 - 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists - Google Patents

4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists

Info

Publication number
PL351794A1
PL351794A1 PL00351794A PL35179400A PL351794A1 PL 351794 A1 PL351794 A1 PL 351794A1 PL 00351794 A PL00351794 A PL 00351794A PL 35179400 A PL35179400 A PL 35179400A PL 351794 A1 PL351794 A1 PL 351794A1
Authority
PL
Poland
Prior art keywords
methoxy
heterocyclysulfonamidyl
phenoxy
pyridyl
preparation
Prior art date
Application number
PL00351794A
Other versions
PL198815B1 (en
Inventor
Volker Breu
Philippe Coassolo
Werner Neidhart
Sebastien Roux
Peter Weiss
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL351794A1 publication Critical patent/PL351794A1/en
Publication of PL198815B1 publication Critical patent/PL198815B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL351794A 1999-03-03 2000-02-28 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists PL198815B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99104306 1999-03-03
PCT/EP2000/001660 WO2000052007A1 (en) 1999-03-03 2000-02-28 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists

Publications (2)

Publication Number Publication Date
PL351794A1 true PL351794A1 (en) 2003-06-16
PL198815B1 PL198815B1 (en) 2008-07-31

Family

ID=8237697

Family Applications (1)

Application Number Title Priority Date Filing Date
PL351794A PL198815B1 (en) 1999-03-03 2000-02-28 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists

Country Status (30)

Country Link
US (2) US6417360B1 (en)
EP (1) EP1185525B1 (en)
JP (1) JP3488203B2 (en)
KR (1) KR100478798B1 (en)
CN (1) CN1342158B (en)
AR (1) AR044720A1 (en)
AT (1) ATE353325T1 (en)
AU (1) AU756738B2 (en)
BR (1) BR0008717A (en)
CA (1) CA2364906C (en)
CY (1) CY1108002T1 (en)
CZ (1) CZ300324B6 (en)
DE (1) DE60033280T2 (en)
DK (1) DK1185525T3 (en)
ES (1) ES2280198T3 (en)
HK (1) HK1044943B (en)
HR (1) HRP20010630B1 (en)
HU (1) HUP0200080A3 (en)
ID (1) ID30484A (en)
IL (1) IL145051A0 (en)
MA (1) MA26776A1 (en)
NO (1) NO320809B1 (en)
NZ (1) NZ513671A (en)
PL (1) PL198815B1 (en)
PT (1) PT1185525E (en)
RS (1) RS50109B (en)
RU (1) RU2201928C1 (en)
TR (1) TR200102562T2 (en)
WO (1) WO2000052007A1 (en)
ZA (1) ZA200107157B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US20020184047A1 (en) * 2001-04-03 2002-12-05 Plotnick Michael A. Universal ad queue
EP1454625A1 (en) * 2003-03-06 2004-09-08 Speedel Development AG Pyridylsulfonamidyl-pyrimidines for the treatment of diabetic nephropathies
EP1595880A1 (en) * 2004-05-13 2005-11-16 Speedel Pharma AG Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
JP2009507890A (en) * 2005-09-12 2009-02-26 シュペーデル・ファルマ・アーゲー Pyridylsulfonamidyl-pyrimidines for the prevention of vascular graft dysfunction
RU2435585C2 (en) * 2006-04-13 2011-12-10 Актелион Фармасьютиклз Лтд Antagonists of endoteline receptor intended for early stage of idiopatic pulmonary fibrosis
EP1938812A1 (en) * 2006-12-22 2008-07-02 Speedel Pharma AG Pharmaceutical composition using aliskiren and avosentan
US20100093758A1 (en) * 2008-07-23 2010-04-15 Auspex Pharmaceuticals, Inc. Pyridine sulfonamide modulators of endothelin-a receptor
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
KR101936054B1 (en) 2017-06-23 2019-01-11 한국과학기술연구원 Anti-inflammatory 6-phenoxypyrimidine derivatives, process for their preparation and pharmaceutical composition containing them
TW202329952A (en) 2021-12-17 2023-08-01 瑞士商愛杜西亞製藥有限公司 A process for the preparation of clazosentan disodium salt

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2162630C (en) 1994-11-25 2007-05-01 Volker Breu Sulfonamides
CN1064965C (en) * 1994-11-25 2001-04-25 弗·哈夫曼-拉罗切有限公司 Novel sulfonamides compound and its use as medicine
US5837708A (en) 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
TW313568B (en) * 1994-12-20 1997-08-21 Hoffmann La Roche
ATE267808T1 (en) 1997-08-19 2004-06-15 Hoffmann La Roche METHOD FOR PRODUCING 2,5-DISUBSTITUTED PYRIDINES
TWI284642B (en) * 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides

Also Published As

Publication number Publication date
HRP20010630A2 (en) 2002-08-31
US6417360B1 (en) 2002-07-09
DE60033280D1 (en) 2007-03-22
YU62801A (en) 2004-07-15
CZ300324B6 (en) 2009-04-22
ES2280198T3 (en) 2007-09-16
WO2000052007A1 (en) 2000-09-08
RU2201928C1 (en) 2003-04-10
NO20014224D0 (en) 2001-08-31
JP2002538156A (en) 2002-11-12
HK1044943B (en) 2013-03-22
US20020137933A1 (en) 2002-09-26
EP1185525B1 (en) 2007-02-07
ZA200107157B (en) 2002-11-29
PT1185525E (en) 2007-05-31
NO320809B1 (en) 2006-01-30
MA26776A1 (en) 2004-12-20
CA2364906A1 (en) 2000-09-08
HK1044943A1 (en) 2002-11-08
DK1185525T3 (en) 2007-06-04
KR20010102480A (en) 2001-11-15
RS50109B (en) 2009-03-25
CA2364906C (en) 2006-01-10
AU3161100A (en) 2000-09-21
HUP0200080A2 (en) 2002-06-29
NZ513671A (en) 2003-04-29
ID30484A (en) 2001-12-13
DE60033280T2 (en) 2007-11-22
TR200102562T2 (en) 2002-02-21
PL198815B1 (en) 2008-07-31
EP1185525A1 (en) 2002-03-13
ATE353325T1 (en) 2007-02-15
HRP20010630B1 (en) 2010-08-31
CZ20013108A3 (en) 2002-02-13
JP3488203B2 (en) 2004-01-19
KR100478798B1 (en) 2005-03-24
CN1342158A (en) 2002-03-27
AU756738B2 (en) 2003-01-23
NO20014224L (en) 2001-08-31
AR044720A1 (en) 2005-10-05
CN1342158B (en) 2012-06-06
RU2001126348A (en) 2004-03-20
CY1108002T1 (en) 2013-09-04
IL145051A0 (en) 2002-06-30
BR0008717A (en) 2001-12-26
HUP0200080A3 (en) 2003-01-28
US6521631B2 (en) 2003-02-18

Similar Documents

Publication Publication Date Title
HUP0301654A3 (en) Novel n-pyrimidinyl-sulfamides, their use as endothelin receptor antagonists and pharmaceutical compositions containing them
HUP0302969A3 (en) Npyy5 antagonists, pharmaceutical compositions containing them and their use
HK1048999A1 (en) Azepinoindole derivatives, their preparation and use thereof
PL350093A1 (en) 4-(heterocyclylsulfonamido) -5-methoxy-6- (2-methoxyphenoxy) -2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists
IL152700A0 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinc receptor antagonists
HK1044942A1 (en) 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
HUP0202202A3 (en) Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof
EP1254116A4 (en) Alpha v integrin receptor antagonists
AU4667101A (en) Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
EP1252162A4 (en) Alpha v integrin receptor antagonists
IL135451A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
AU2001290772A1 (en) Alpha v integrin receptor antagonists
PL351794A1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
AU9259801A (en) Alpha v integrin receptor antagonists
HUP0204113A3 (en) Novel integrin receptor antagonists, pharmaceutical compositions containing them and their use
AUPQ570100A0 (en) Beta-alanine derivatives and their use as receptor antagonists
ZA985277B (en) Novel ß-amino and ß-azido carboxylic and acid derivatives, their preparation and use as endothelin receptor antagonists.
HUP0202710A3 (en) Vitronectin receptor antagonists, pharmaceutical compositions containing them and their use
AU5861900A (en) Receptor agonists and antagonists
HK1049151A1 (en) Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists
EP1169042A4 (en) Dibenzo-azepine derivatives as alpha v integrin receptor antagonists
IL135452A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
IL143451A0 (en) NEW- β-AMIDE AND β-SULFONAMIDE CARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS
ZA9810425B (en) Novel heterocyclically substituted Ó-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists.
IL146800A0 (en) Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their preparation and use as endothelin receptor antagonists